For many living with lower-risk #MDS, the burden of transfusion dependence reaches far beyond the clinic. Dr. Valeria Santini – a long-time principal investigator in our studies and an upcoming #ASH25 presenter – shares why reducing transfusion burden remains one of the most meaningful goals in care. Watch as we continue counting down to ASH 2025 and spotlighting the science that’s redefining what’s possible for patients.
Geron Corporation
Biotechnology Research
Foster City, California 21,059 followers
Changing lives by changing the course of blood cancer.
About us
Geron is a biopharmaceutical company that is charting a new course with the goal to deliver innovative treatment options for people living with blood cancer. Our tireless pursuit to improve outcomes for these patients resulted in the U.S. approval of the first ever telomerase inhibitor for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. As the sole company with an oligonucleotide telomerase inhibitor approved by the FDA, we feel a deep urgency to bring the potential power of telomerase inhibition to patients in need. We are conducting research in other blood cancers with high unmet need beyond LR-MDS, with ongoing clinical trials across other hematologic malignancies, including a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF). We are proud of the impact this Nobel-winning science is having in the fight against blood cancers. At Geron, we are united by a shared purpose: Every individual in every role can meaningfully contribute to our mission to change lives by changing the course of blood cancer. With a culture rooted in courage and determination, we will continue to innovate and pursue new possibilities for patients. To learn more, visit www.geron.com. Geron’s Community Guidelines: https://www.geron.com/CommunityGuidelines/
- Website
-
http://www.geron.com
External link for Geron Corporation
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Foster City, California
- Type
- Public Company
- Founded
- 1992
- Specialties
- Oncology, Hematologic Malignancies, and Telomerase Inhibition
Locations
-
Get directions
919 E Hillsdale Blvd
Foster City, California 94404, US
Employees at Geron Corporation
Updates
-
Geron’s leadership captured exactly why we are excited and proud to be part of our organization. As we look ahead to 2026 and beyond, it’s clear that everyone across #TeamGeron plays a critical role in advancing our mission to bring therapies to the clinicians and patients who need it most. You can watch the full Stifel webcast here: https://lnkd.in/dHXFZsXX
This week, I joined Steve Willey at the 2025 Stifel Healthcare Conference for a fireside chat alongside our CMO, Joseph E. Eid We highlighted what makes us at Geron motivated every day: 💡We have a medicine with the potential to meaningfully impact people living with lower-risk #MDS 💡We have a team that deeply believes in the science – and understands the urgency of getting it into the hands of clinicians, for the appropriate patients. 💡We are aligned on our push to make 2026 our growth year. We look forward to sharing additional clinical and scientific data at #ASH25 next month, reinforcing our conviction in telomerase inhibition and the opportunity ahead.
-
-
We have released our Q3 financial results and recent business highlights. With recent leadership additions, we can improve our alignment and build an execution-oriented organization that can bring the promise of telomerase inhibition to more lower-risk #MDS patients. Learn more: https://lnkd.in/e-C27H3V
-
-
We are pleased to share that Harout Semerjian, Chief Executive Officer, is planning to participate in fireside chats at the 2025 Stifel and Evercore Healthcare Conferences on Nov. 11 and Dec. 2. A webcast of the events will be available for replay. Find more details here: https://lnkd.in/eBMEN4hK
-
-
The countdown to #ASH25 begins. We’re pleased to share that five abstracts – including one oral and four posters – highlighting Geron’s commitment to advancing research in myeloid hematologic malignancies have been accepted for presentation at the American Society of Hematology Annual Meeting, December 6-9 in Orlando, Florida. These presentations reflect how telomerase inhibition continues to shape what’s possible for patients living with lower-risk #MDS and #myelofibrosis – and for the broader #hematology community. 🔥 Follow #TeamGeron for more updates as we share our excitement and scientific insights leading up to Orlando. Read more and add these ASH presentations to your agenda: https://lnkd.in/ekwx-7WW
-
Teamwork never goes out of season – especially for #TeamGeron. 🧡🎃 👻 Here’s to a fun, festive, and safe Halloween for all!
-
-
Meet Dana Clark , PharmD, BCOP, Director of Scientific Training and Excellence at Geron. After years as a hematology/oncology clinical pharmacist, Dana joined Geron to help bring novel therapies for myeloid malignancies to patients, a mission that she says gives her true purpose. At Geron, Dana helps ensure the Medical Affairs team has the information and resources they need to excel and thrives on being surrounded by #TeamGeron colleagues who share the same patient-first mindset. This #PharmacistsMonth and every month, we’re grateful to Dana for her commitment, expertise, and the impact she makes every day at Geron. #APhM2025
-
October was a month of collaboration across the oncology and biotech communities. From #JADPROLive and #FLASCO to #JSH, #ACCC, #LLM, #BIOSpace2025, and the final #MoveforMDS walk in Boston, our conversations and connections reaffirmed what drives #TeamGeron every day – advancing science for patients. With #ASH25 on the horizon, we're grateful for the opportunity to learn from and engage with the clinicians, researchers, and advocates driving progress in #hematology and oncology care.
-
We plan to release our Q3 financial results and business highlights on November 5 at 8 a.m. ET. Learn more: https://lnkd.in/ee2_vxRb
-
-
When more people can speak the language of #MDS, they can better understand the patient journey. In honor of MDS World Awareness Day tomorrow, some members of #TeamGeron took on the challenge to break down some common words that appear in research and conversations around MDS. #MDSWAD2025